Dishman Carbogen Amcis Ltd

Dishman Carbogen Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dishman Carbogen Amcis Ltd

₹ 234 1.14%
24 Apr 3:51 p.m.
dishmangroup.com BSE: 540701 NSE : DCAL
About

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]

Key Points

Business Segments
CRAMS Vertical (~77% of total revenues)[1]
The company is an integrated Contract Research & Manufacturing Services (CRAMS) player with strong capabilities across the value chain. It assists drug innovators in development and optimization of processes for novel drug molecules in various stages of the development process. [2]
Presently, the company has a total of 27 commercialized molecules and 17 molecules in phase-3 (last stage) of manufacturing optimization. During the year 3 new molecules were commercialized. [3]
It earns ~83% of CRAMS revenues from Switzerland, France & China. [4]

Website BSE NSE
  • Market Cap ₹ 3,675 Cr.
  • Current Price ₹ 234
  • High / Low ₹ 283 / 113
  • Stock P/E
  • Book Value ₹ 261
  • Dividend Yield 0.00 %
  • ROCE -0.75 %
  • ROE -1.34 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.91 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -3.23% over past five years.
  • Company has a low return on equity of -2.41% over last 3 years.
  • Earnings include an other income of Rs.78.0 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
60 86 63 84 74 84 104 107 78 113 70 60 87
77 76 59 58 69 81 101 105 82 107 75 63 84
Operating Profit -17 10 4 26 5 3 3 1 -3 6 -5 -3 3
OPM % -28% 12% 6% 31% 6% 4% 3% 1% -4% 6% -7% -5% 4%
19 5 18 13 16 8 4 21 10 15 14 36 13
Interest 8 10 8 8 11 10 13 14 15 17 18 17 17
Depreciation 36 35 35 35 35 34 35 35 3 23 25 25 26
Profit before tax -41 -30 -21 -5 -26 -33 -40 -27 -10 -19 -33 -9 -27
Tax % 34% -379% 33% 38% 23% 114% 37% 36% 37% 47% 35% 38% 33%
-27 -142 -14 -3 -20 5 -25 -17 -7 -10 -21 -6 -18
EPS in Rs -1.72 -9.06 -0.89 -0.18 -1.25 0.31 -1.58 -1.10 -0.42 -0.65 -1.36 -0.37 -1.16
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
0 7 451 474 549 581 200 307 403 329
0 5 303 308 356 401 253 267 394 328
Operating Profit -0 2 148 166 194 179 -53 40 9 2
OPM % 25% 33% 35% 35% 31% -26% 13% 2% 0%
0 0 71 66 72 64 59 53 49 78
Interest 1 1 39 35 47 47 34 37 58 69
Depreciation 0 0 136 134 136 141 141 140 96 99
Profit before tax -0 1 44 62 82 55 -169 -84 -96 -89
Tax % 0% 12% 45% 40% 31% 31% -38% 63% 39%
-0 1 24 37 56 39 -233 -32 -59 -56
EPS in Rs 2.30 3.47 2.46 -14.85 -2.01 -3.75 -3.54
Dividend Payout % 0% 0% 0% 0% 6% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -3%
3 Years: -12%
TTM: -12%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -37%
Stock Price CAGR
10 Years: %
5 Years: 0%
3 Years: 16%
1 Year: 71%
Return on Equity
10 Years: %
5 Years: -1%
3 Years: -2%
Last Year: -1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 0 0 32 32 31 31 31 31 31
Reserves -1 0 4,771 4,759 4,860 4,764 4,643 4,200 4,083 4,064
10 9 445 622 584 573 538 535 593 615
3 3 321 394 339 366 339 448 473 468
Total Liabilities 12 12 5,537 5,807 5,816 5,735 5,552 5,214 5,181 5,179
0 0 1,927 1,853 1,715 1,633 1,510 1,356 1,382 1,448
CWIP 0 0 41 48 70 89 121 118 143 65
Investments 0 0 2,761 2,937 2,907 2,900 2,882 3,032 2,913 2,898
12 12 808 969 1,124 1,113 1,039 708 743 768
Total Assets 12 12 5,537 5,807 5,816 5,735 5,552 5,214 5,181 5,179

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-1 3 270 20 120 197 -2 227 -53
0 0 -16 -175 -24 -74 62 -173 41
1 -2 -225 142 -85 -124 -71 -46 1
Net Cash Flow -0 1 29 -12 10 -2 -10 9 -11

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 0 58 108 86 91 217 78 133
Inventory Days 390 397 500 390 690 723 389
Days Payable 149 207 210 157 204 198 182
Cash Conversion Cycle 0 298 298 376 324 703 604 340
Working Capital Days 467 278 288 284 230 785 362 267
ROCE % 21% 3% 2% 2% 2% -2% -1% -1%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32%
5.91% 4.40% 4.60% 5.50% 5.85% 6.20% 7.20% 9.34% 8.90% 8.80% 8.60% 8.70%
6.75% 6.15% 6.31% 6.91% 6.63% 4.26% 3.86% 2.55% 3.13% 3.51% 3.68% 2.36%
28.01% 30.13% 29.77% 28.26% 28.19% 30.22% 29.61% 28.79% 28.65% 28.37% 28.39% 29.63%
No. of Shareholders 54,07760,72654,66256,32256,98659,65461,17556,58356,22156,27252,33650,656

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls